Base-Case Analysis Results, Various Alendronate Costs.

a<p>Incremental cost-effectiveness of osteoporosis screening followed by alendronate treatment, compared to no screening with treatment only if fracture occurs; in 2010 US dollars per quality-adjusted life-year (QALY).</p>b<p>Lifetime direct costs saved.</p

Model Schematic.

<p>A simplified and partial representation of the full model.</p

Probabilistic Sensitivity Analysis Cost-Effectiveness Acceptability Curves.

<p>Probabilistic Sensitivity Analysis Cost-Effectiveness Acceptability Curves.</p